ONLY FOR HEALTH MEDIA
Almirall presents new data on biologics for psoriasis and atopic dermatitis, highlighting the potential of therapies like tildrakizumab and lebrikizumab to positively impact patient outcomes.
Almirall’s broad presence at the 33rd EADV Congress coincides with the company’s 80th anniversary, highlighting eight decades of dedication to innovation and delivering solutions to positively impact people’s health and lives
Ebglyss (lebrikizumab)
Ebglyss is a medicine used to treat moderate to severe atopic dermatitis (also known as atopic eczema, when the skin is itchy, red and dry). It is used in adults and children aged 12 years and over weighing at least 40 kg. It is used in patients for whom treatment applied directly to the skin cannot be used or is not sufficient.
Ebglyss contains the active substance lebrikizumab.
New clinical data on Lebrikizumab demonstrate sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis (presented as a late-breaker). Additional new data include response rates in absolute values and long-term data in patients that are either inadequately controlled or not eligible for cyclosporine treatment
- Each trial consisted of two distinct periods: a 16-week induction period followed by a 36-week
maintenance period.1 - The outcomes of the initial 16-week period, referred to as the induction period, are thoroughly
detailed in the upcoming results.1
| 1st Author | Title: lebri-related disclosures | Format |
| Thaçi et al | Efficacy and Safety of Lebrikizumab Is Maintained Up to 3 Years in Patients With Moderate-to-Severe Atopic Dermatitis: ADvocate1, ADvocate2 to ADjoin Long-Term Extension Trial | Latebreaking news |
| Thaçi et al | Absolute EASI response achieved with lebrikizumab over 52 weeks in patients with moderate-to-severe atopic dermatitis | Poster |
| Warren et al | Improvement across disease dimensions with lebrikizumab in combination with topical corticosteroids in atopic dermatitis inadequately controlled or ineligible to cyclosporine: results from the ADvantage study | Poster |
| Bieber et al | Number needed to treat with lebrikizumab monotherapy at Week 16 in patients with moderate-to-severe atopic dermatitis | Poster |
| Weidinger et al | Absolute response of lebrikizumab at Week 52 in patients with moderate-to-severe atopic dermatitis who did not achieve protocol-defined response after initial 16 weeks of treatment | Poster |
| Warren et al. | Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients inadequately controlled or ineligible for cyclosporine: week 52 results of a phase 3 clinical study (ADvantage) | Poster |
| Thaçi et al. | Absolute itch and quality of life response with lebrikizumab through 52 weeks | Poster |
| Eyerich et al. | Lebrikizumab as monotherapy improves the signs of moderate-to-severe atopic dermatitis across different body regions including head and neck over one year of treatment | Poster |
| Thaçi et al | Absolute EASI response achieved by lebrikizumab over 16 weeks in patients with moderate-to-severe atopic dermatitis | Poster |
| Tanaka et al | Lebrikizumab demonstrated early improvement in both clinician and patient reported outcomes as measured by SCORAD in Japanese patients with moderate-to-severe atopic dermatitis | Poster |
| Wiseman et al | Changes in Quality of Life Measured by EQ-5D-5L in Patients Treated With Lebrikizumab for Moderate-to-Severe Atopic Dermatitis | Poster |
Ilumetri (tildrakizumab)
Ilumetri is a medicine that acts on the immune system and is used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. It is used in adults with moderate to severe disease for whom treatments applied to the skin are not suitable.
Ilumetri contains the active substance tildrakizumab.
Impact of the treatment of psoriasis on patient wellbeing: new data from the POSITIVE study
Almirall will unveil new interim data on the treatment of adults with moderate-to-severe plaque psoriasis with tidrakizumab at 52 weeks from the POSITIVE clinical study. The POSITIVE study is the first clinical trial in dermatology to use the WHO-5 Wellbeing Index as a primary endpoint. The 5-item World Health Organization Wellbeing Index is a validated questionnaire that assesses health-related subjective psychological wellbeing in a variety of chronic diseases. The different sub-analyses presented during the congress reinforce the effectiveness of tildrakizumab on signs and symptoms in skin and beyond.
Author | Title | Abstract nº |
Magnolo N, Kirsch A, Buhk RT | Improving the well-being of patients with moderate to severe plaque psoriasis and involvement of impactful areas with Tildrakizumab | 4476 |
Weger W, Gruber B, Ratzinger G, Sator P-G | Effectiveness and Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) of tildrakizumab patients with nail psoriasis: 52-week results from the phase IV POSITIVE Austrian subset | P3348 |
Augustin M, Sommer R, Reguiai Z, Gerdes S, Dauden E, Weger W, Maul J-T, Laws P, Naldi L, Ghislain P-D, de Jong E, Mburu S, Koscielny V, Massana E, Kasujee I, Mrowietz U | Effectiveness of tildrakizumab in patients with moderate-to-severe psoriasis located in special areas: 52-week results from the POSITIVE study | P3343 |
Mrowietz U, Sommer R, Reguiai Z, Gerdes S, Dauden E, Weger W, Maul J-T, Laws P, Naldi L, Ghislain P-D, de Jong E, Mburu S, Koscielny V, Massana E, Kasujee I, Augustin M | High effectiveness of tildrakizumab in bio-naïve and bio-experienced patients with moderate-to-severe psoriasis: 52-week results from the POSITIVE study | P3341 |
Mrowietz U, Sommer R, Reguiai Z, Gerdes S, Dauden E, Weger W, Maul J-T, Laws P, Naldi L, Ghislain P-D, de Jong E, Mburu S, Koscielny V, Massana E, Kasujee I, Augustin M | High effectiveness of tildrakizumab regardless of baseline characteristics in patients with moderate-to-severe psoriasis: 52-week results from the POSITIVE study | P3340 |
Sommer R, Augustin M, Reguiai Z, Gerdes S, Dauden E, Weger W, Maul J-T, Laws P, Naldi L, Ghislain P-D, de Jong E, Mburu S, Koscielny V, Massana E, Kasujee I, Mrowietz U | Patient-reported well-being using tildrakizumab for psoriasis in a real-world setting: 52-week interim data of the phase IV POSITIVE study | P3188 |
Sommer R, Augustin M, Reguiai Z, Gerdes S, Dauden E, Weger W, Maul J-T, Laws P, Naldi L, Ghislain P-D, de Jong E, Mburu S, Koscielny V, Massana E, Kasujee I, Mrowietz U | Safety of tildrakizumab in patients with moderate-to-severe psoriasis: 52-week data from the phase IV POSITIVE study | P3339 |
Mrowietz U, Augustin M, Reguiai Z, Gerdes S, Dauden E, Weger W, Maul J-T, Laws P, Naldi L, Ghislain P-D, de Jong E, Mburu S, Koscielny V, Massana E, Kasujee I, Sommer R | Effectiveness of tildrakizumab for itch, pain, and fatigue in patients with moderate-to-severe psoriasis: 52-week results from the real-world POSITIVE study | P3346 |
Augustin M, Sommer R, Reguiai Z, Gerdes S, Dauden E, Weger W, Maul J-T, Laws P, Naldi L, Ghislain P-D, de Jong E, Mburu S, Koscielny V, Massana E, Kasujee I, Mrowietz U | Quality of life, work productivity and treatment satisfaction with tildrakizumab in moderate-to-severe psoriasis patients: 52-week interim data of the real-world POSITIVE study | P3347 |
Mrowietz U, Sommer R, Reguiai Z, Gerdes S, Dauden E, Weger W, Maul J-T, Laws P, Naldi L, Ghislain P-D, de Jong E, Mburu S, Koscielny V, Massana E, Kasujee I, Augustin M | Impact of patient psoriasis on partner well-being in a real-world setting: 52-week interim data of the phase IV POSITIVE study | P3344 |
Armstrong AW, Blauvelt A, Lebwohl M, Asahina A, Gogineni R, Griffiths CEM | Efficacy and safety of tildrakizumab through Week 28 in patients with early vs late-onset moderate-to-severe plaque psoriasis: A post hoc analysis of reSURFACE 1 and reSURFACE 2 | P3177 |
Impressions of the congress
About Almirall
Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients’ world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs.
Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker:ALM, total revenue in 2023: €898.8 MM, 1900 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.
For more information, please visit https://www.almirall.com/
Corporate Communications: Investor Relations
corporate.communication@almirall.com investors@almirall.com
Phone: (+34) 659 614 173 Phone: (+34) 93 291 30 87
.